Drug intelligence / Profile preview

TEC-002

Development stage: Unknown
Lead developer: Teclison
Modality: Small Molecules

Overview

TEC-002 is an investigational antineoplastic agent being developed by Teclison for the treatment of solid tumors. It is described as a tumor necrosis inducer with immune-activating properties. The drug's mechanism of action involves the induction of tumor cell death (necrosis), which subsequently facilitates the release and presentation of tumor antigens to the immune system. This process is intended to trigger a physiological immune response against the malignancy. TEC-002 is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on TEC-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEC-002.

Explore the full profile